PSG Report Finds Payers Reassessing GLP-1 Coverage, PBM Models, and Cost-Sharing Strategies

DALLAS--(BUSINESS WIRE)--Pharmaceutical Strategies Group (“PSG”), an EPIC company, today released its 2026 Trends in Drug Benefit Design Report, sponsored by Transcarent, highlighting how payers are adjusting pharmacy benefit strategies amid evolving GLP-1 utilization, heightened focus on alternative pharmacy benefit management (PBM) models, and rising pressure around drug pricing and member cost sharing. PSG’s annual research has tracked trends shaping drug benefit design and management for mo